Claremore Compounding Center, Inc., Claremore, OK

Is Claremore Compounding Center, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Claremore Compounding Center, Inc. hold a Oklahoma pharmacy license?

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.

Has Claremore Compounding Center, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Aug 21, 2020), 1 state handoff letter (Apr 28, 2021) and 1 FMD-145 letter (Apr 28, 2021) for Claremore Compounding Center, Inc. State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Claremore Compounding Center, Inc.
Location
Claremore, OK
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Apr 28, 2021
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 3 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Claremore Compounding Center, Inc., a 503A facility, with 4 dated actions.

Document
Apr 28, 2021State handoff letterState Handoff Letter Issued 04/28/2021Not linked by FDA
Apr 28, 2021FMD-145 letterFMD-145 Letter Issued 04/28/2021Not linked by FDA
Aug 21, 2020Untitled letterUntitled Letter Issued 08/21/2020FDA copy (archived)
Jan 24, 2020Form 483483 Issued 01/24/2020FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Claremore Compounding Center, Inc., Claremore, OK (FEI number 3004549371), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jan 24, 2020Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30045493711115817

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jan 13, 2020 to Jan 24, 2020: 3 observations

Firm on the cover
, Claremore, OK 74017-3068
FEI number
3004549371
Establishment type on the cover
Producer of non-sterile drug products
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, your firm is using orange food color that is non-pharmaceutical grade to make drug products. Examples include lot #95806 of hydrocodone/dextromethorphan 10mg/10mg capsules made on 12/10/19 and lot #94010 of hydrocodone/dextromethorphan 5mg/5mg capsules made on 9/11/1 9.

Observation 2

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm does not have a written stability testing program to determine Beyond Use Dates (BUD)/expiration dates placed on all your drug products. For example,

a) Lot #95371 of Dry Skin Moisturizing (OTC) 5% -1% Cream ( containing <Redacted B4> and hydrocortisone) made on 11 /20/19 was assigned a BUD of 360 days.

b) Lot #94404 of CCC Cold Max 100-5-10-2mg per 5mL suspension ( containing guaifenesin, phenylephrine HCI , chlorpheniramine Maleate and dextromethorphan hydrobromide) made on 10/1/19 was assigned a BUD of 180 days.

c) Lot #94402 of CCC Coughist PE 100-5-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI, and chlorpheniramine maleate) made on 10/1/19 was assigned a BUD of 180 days.

d) Jungle Juice Liquid (containing <Redacted B4> and lidocaine): Lot #92698 made on 7/9/1 9, lot #93496 made on 8/16719, and lot ~21-749 made on 10/17/19 were each assigned a BUD of 360 days. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically, your firm does not conduct routine testing for potency for all drug products produced by your firm. Examples include the following,

a) Lot #95371 of Dry Skin Moisturizing (OTC) 5% -1% Cream (containing <Redacted B4> and hydrocortisone) made on 11/20/19.

b) Lot #94404 of CCC Cold Max 100-5-10-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI , chlorpheniramine Maleate and dextromethorphan hydrobromide) made on 10/1/19.

c) Lot #94402 of CCC Coughist PE 100-5-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI , and chloq::iheniramine maleate) made on 10/1/19.

d) Jungle Juice Liquid (containing <Redacted B4> and lidocaine): Lot #92698 made on 7/9/19, lot #93496 made on 8/16/19, and lot #94749 made on 10/17/19.

l(~) ("1-)

e) Jungle Ointment (containing <Redacted B4> hydrocortisone and lidocaine): Lot #92655 made on 7/5/19 and lot #92915 made on 7/19/19.

l ...

Read the full 483 (PDF on fda.gov)

State board of pharmacy records

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.